SenzaGen
SenzaGen is a Swedish life science company focused on nonanimal testing for chemical safety and product efficacy. Its core offering combines proprietary GARD® testing methods, consulting services, and laboratory work delivered through its own facilities in Sweden and Italy, supported by a network of partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNonanimal tests used to assess skin and respiratory sensitization and chemical safety.
Human-relevant preclinical testing using tissue models and organoids for product performance.
Scientific and regulatory guidance that helps customers select and interpret tests.
Testing capacity and market access delivered through distributors and license partners.
Customers
SenzaGen sells primarily to large multinational companies that need testing during product development, reformulation, and regulatory submission. Its customer base spans cosmetics, chemicals, medical devices, pharmaceuticals, and nutrition/food additives, where buyers need evidence that products meet safety requirements without animal testing.
Buy GARD® and related lab services directly for recurring regulatory and development testing.
Use skin sensitization and efficacy testing when launching or reformulating products.
Buy toxicology testing to support product safety and regulatory compliance.
Use sensitization testing to support ISO and regulatory requirements.
Partners extend market reach and provide flexible testing capacity.
Strategy
SenzaGen’s strategy is built around expanding adoption of GARD® through regulatory approvals, technology upgrades, and broader market acceptance. It combines direct sales to large recurring customers with partner channels to scale internationally while building a larger portfolio of nonanimal test methods.
Regulatory approvals increase customer adoption and support repeat testing demand.
Large recurring customers fit the lab-based model and improve repeat order visibility.
Distributors and licensees extend reach without requiring full local infrastructure.
A broader portfolio increases addressable markets and reduces reliance on one assay family.
Geography
SenzaGen is headquartered in Lund, Sweden and operates GLP-approved laboratories in Sweden and Italy. The company’s commercial focus is Europe, with selective targeting of large multinational customers in North America, especially the United States, and it also uses international distributors and license partners to broaden reach.
Risks
SenzaGen faces execution risk in market expansion, product development, and reliance on partners that help scale sales and capacity. As a testing company with proprietary methods, it also depends on regulatory acceptance, patent protection, customer adoption, and access to capital to fund growth initiatives.
- Market growth and expansion executionImpact: HighLikelihood: Medium
Entering new countries and regions can create delays, organizational strain, and lost revenue.
Exposure: New market entry and sales expansion
- Product development and regulatory adoptionImpact: HighLikelihood: Medium
New tests need validation and acceptance before they can generate meaningful revenue.
Exposure: New assay launches and standards inclusion
- Distributor and license partner dependenceImpact: HighLikelihood: Low
A small but important share of revenue and capacity depends on third-party partners fulfilling obligations.
Exposure: Partner sales and flexible testing capacity
- Financing needsImpact: MediumLikelihood: Medium
Growth initiatives may require additional funding if market penetration is slower than planned.
Exposure: Capital raises and liquidity planning
- Patent and IP protectionImpact: MediumLikelihood: Medium
Commercial value depends on patents and proprietary methods remaining defensible.
Exposure: GARD® platform and related methods
Accounting
Judgemental itemsLaboratory and office leases are capitalized, changing operating expense presentation and leverage metrics.
Impact: Right-of-use assets, lease liabilities, depreciation, and interest expense
Revenue timing depends on when tests are performed and accepted under customer contracts.
Impact: Quarterly revenue volatility and contract asset/liability balances
Acquired businesses and technology require impairment review if expected cash flows weaken.
Impact: Potential non-cash impairment charges
The company has restated prior periods under IFRS, affecting trend analysis.
Impact: Comparability between 2024 K3 and IFRS figures
Similar listed companies
Publicly listed companies with a comparable business focus.
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
SenesTech, Inc.
SNES · Agricultural Chemicals
Essity A
ESSITY-B · Consumer Staples
Essity Aktiebolag is a global hygiene and health company headquartered in Sweden.
Essity B
ESSITY-B · Consumer Staples
Essity Aktiebolag (publ) is a global hygiene and health company that develops, produces, and sells personal care and tissue products.
NervGen Pharma Corp
NGEN · Pharmaceutical Preparations
Sana Biotechnology, Inc.
SANA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026